Researchers have found that a single enzyme called PI5P4Kα can be targeted to kill prostate cancer. The discovery is the first of its kind and could help tackle treatment resistance in prostate cancer. Additionally, it could lead to better treatment options for other types of cancer, including those affecting the breast, skin, and pancreas.
A new study has identified a potential breakthrough in prostate cancer treatment. Researchers at the University of Virginia School of Medicine have discovered a way to kill resistant cancer cells by targeting a key enzyme. The enzyme, called DCTPP1, is crucial for the survival of cancer cells that have become resistant to chemotherapy and other treatments.
The team discovered that cancer cells with high levels of DCTPP1 were more resistant to chemotherapy and radiation. They then used a molecule called DT-010 to target and inhibit the enzyme. The molecule was effective at killing cancer cells, even those that were resistant to other treatments.
Continue reading… “Revolutionary Prostate Cancer Treatment Kills Resistant Cells by Targeting Key Enzyme”